Core Insights - Anixa Biosciences has announced the final results of its Phase 1 clinical trial for a breast cancer vaccine, which will be presented at the 2025 San Antonio Breast Cancer Symposium [1][2][3] - The trial, funded by the U.S. Department of Defense, evaluated the safety and immunogenicity of an alpha-lactalbumin (aLA) vaccine for breast cancer [2][3] - The results are expected to inform discussions with the FDA and advance plans for Phase 2 development [1][3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4] - The company’s vaccine technologies target "retired" proteins expressed in certain cancers, including breast and ovarian cancer, developed at Cleveland Clinic and exclusively licensed to Anixa [4] - Anixa's business model involves partnerships with leading research institutions to explore emerging technologies for further development and commercialization [4]

Core Insights - Anixa Biosciences, Inc. will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8 to 10, 2025, in New York City [1][2] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [2] - The company utilizes a novel CAR-T technology called chimeric endocrine receptor-T cell (CER-T) technology, which differentiates itself by using the natural ligand of the FSHR receptor, FSH, to bind to tumor cells [2] - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other vaccines targeting high incidence malignancies in lung, colon, and prostate cancers [2] - The vaccines are based on immunizing against "retired" proteins expressed in certain cancer forms, with Cleveland Clinic entitled to royalties and commercialization revenues from these technologies [2] - Anixa's business model involves partnerships with renowned research institutions at all development stages, allowing the company to explore emerging technologies for further development and commercialization [2]

Core Insights - Anixa Biosciences, Inc. is gaining media attention for its breast cancer vaccine, which has the potential to transform breast cancer treatment and prevention [1][2][3] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [5] - The company’s vaccine portfolio includes vaccines for breast and ovarian cancer, developed in collaboration with Cleveland Clinic, targeting various cancers including lung, colon, and prostate [5] Vaccine Mechanism - The breast cancer vaccine is designed to train the immune system to recognize and eliminate cancerous cells by targeting the lactation protein α-lactalbumin, which is expressed in malignant breast cancer cells [2] - This vaccine aims to activate cytotoxic T cells to provide preemptive immune protection against emerging breast tumors [2] Media Coverage - The New York Post and Fox News have featured Anixa's breast cancer vaccine, highlighting its potential impact on breast cancer treatment [1][3]

Core Insights - Anixa Biosciences has made significant progress in its clinical and pre-clinical development programs in 2025, maintaining fiscal discipline while advancing its oncology treatment initiatives [1][5] Financial Performance - The company has maintained an average annual cash burn of approximately $5–6 million, which is significantly lower than typical for development-stage biotechnology companies [2] - In the most recent fiscal year, the cash burn was limited to $7 million while advancing two clinical trials [2] - Anixa ended the most recent quarter with over $17 million in cash and no debt, providing more than two years of operational runway [3] Capital Structure - Anixa has a clean capital structure with approximately 32 million common shares outstanding and no warrants [4] - Directors and senior management have consistently purchased stock on the open market, collectively investing millions of dollars, indicating strong belief in the company's long-term value [4] Clinical Programs - The CAR-T therapy program targeting recurrent, platinum-resistant ovarian cancer is progressing, with three dose-escalation cohorts completed in the Phase 1 trial [6][7] - Encouraging signs of efficacy have been observed, with one patient surviving two years post-treatment, significantly exceeding the typical four-month median survival for this population [7] - The breast cancer vaccine, developed in collaboration with Cleveland Clinic, is nearing enrollment completion in its Phase 1 trial, with over 70% of patients showing protocol-defined immune responses [9][11] Future Milestones - Key milestones for the second half of 2025 include final Phase 1 data for the breast cancer vaccine, anticipated FDA interactions, and the initiation of the fourth cohort for the CAR-T ovarian cancer program [15][17] - The company is preparing to extend its vaccine platform to target prostate, lung, and colon cancers, addressing substantial unmet needs in these areas [13][14]